Back to today’s briefing

Story perspectives

Novo Nordisk's $8.5B Bid Tops Pfizer's, Sparks Antitrust Concerns

10/30/2025

46 10 Full Breakdown

Summary

Story summary

Novo Nordisk has made an unsolicited bid of up to $8.5 billion for Metsera.
The bid surpasses Pfizer's previous offer of $7.3 billion.
Metsera valued shares at $77.75, a 133% premium to the prior closing price.
Pfizer criticized the bid as reckless, alleging it aims to suppress competition and circumvent antitrust laws, and Pfizer has four days to negotiate.

History

Historical Context

The Sherman Antitrust Act, enacted in 1890, marked the beginning of U.S. antitrust law, aiming to prevent monopolistic practices and promote competition. Initially under-enforced, it gained traction during the Progressive Era, with significant cases against companies like Standard Oil. Today, scrutiny of mergers, such as Pfizer's $7.3 billion bid for Metsera, underscores the Act's ongoing relevance in maintaining market fairness.

1 of 2

Story summary

Novo Nordisk has made an unsolicited bid of up to $8.5 billion for Metsera.
The bid surpasses Pfizer's previous offer of $7.3 billion.
Metsera valued shares at $77.75, a 133% premium to the prior closing price.
Pfizer criticized the bid as reckless, alleging it aims to suppress competition and circumvent antitrust laws, and Pfizer has four days to negotiate.

1 / 2